Clevidipine

Clevidipine is an ultra-short-acting, arterial-selective dihydropyridine calcium channel blocker administered intravenously for acute blood pressure management in perioperative and intensive-care settings, metabolised rapidly by blood and tissue esterases. Simson Pharma's Clevidipine reference standard and impurities support the precise potency control required of this critical-care antihypertensive.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Clevidipine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Clevidipine
Clevidipine Impurity E
Methyl 4-(2,3-Dichlorophenyl)-2,6-dimethylnicotinate
Clevidipine Impurity 3
Clevidipine Impurity 1
4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine- 3,5-dicarboxylic acid monomethyl ester
Clevidipine Impurity D
Clevidipine Impurity 2
Clevidipine Impurity F
Clevidipine Nitroso Impurity
Clevidipine Impurity 7
Clevidipine Impurity 5
Clevidipine Impurity 6
Clevidipine Impurity 4
Mixture of Clevidipine Impurity 4 & 7 (E/Z Mixture)
Clevidipine Impurity 9

Metabolites

Clevidipine Carboxylic acid Metabolite
Clevidipine Metabolite H168/79

Isotope Labelled Compounds

Clevidipine-D7
Clevidipine Metabolite 13CD3